将干扰素-α靶向树突状细胞可增强CD8 T细胞对人CD40靶向癌症疫苗的反应。
Targeting interferon-alpha to dendritic cells enhances a CD8 T cell response to a human CD40-targeted cancer vaccine.
作者信息
Graham John P, Authie Pierre, Karolina Palucka A, Zurawski Gerard
机构信息
The Ralph Steinman Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Scott and White Research Institute, Dallas, TX 75204, USA.
The Ralph Steinman Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Scott and White Research Institute, Dallas, TX 75204, USA; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, USA.
出版信息
Vaccine. 2017 Aug 16;35(35 Pt B):4532-4539. doi: 10.1016/j.vaccine.2017.07.032. Epub 2017 Jul 23.
Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8 T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8 T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8 T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.
将抗原靶向抗原呈递细胞（APC）可增强重组蛋白CD8 T细胞疫苗的效力。最近对基于重组蛋白的树突状细胞（DC）靶向疫苗的比较揭示了交叉呈递的差异，并确定CD40是抗原交叉呈递的有效人类DC受体靶点。与体外衍生的单核细胞（mo）DC相反，我们发现，对于针对CD40的癌症疫苗产生抗原特异性IFNγ CD8 T细胞反应而言，干扰素-α（IFNα）刺激人血来源的DC是必要的。重要的是，将IFNα形式的佐剂靶向DC可增强其引发CD8 T细胞产生抗原特异性IFNγ的能力。因此，我们引入了DC佐剂靶向的概念以提高疫苗接种的效力。
Zotero 插件